Literature DB >> 24235067

Efficacy and safety of serial injections of botulinum toxin A in children with spastic cerebral palsy.

Ya-Jie Wang1, Bao-Qin Gao.   

Abstract

BACKGROUND: Botulinum toxin A (BTX-A) has been successfully used as a treatment for children with spastic cerebral palsy; however, the effect of BTX-A on reducing spasticity only lasts a few months, thus serial injections are required. The present study was to evaluate the efficacy and safety of serial injections of BTX-A in children with spastic cerebral palsy.
METHODS: Fifty-two pediatric patients with spastic cerebral palsy, 2-12 years of age (mean age, 4.79 ± 2.70), were retrospectively analyzed. Muscle tone was assessed with the Modified Ashworth Scale, and gait was assessed with the Physician Rating Scale. Assessments were undertaken at baseline, 3 months, and 6 months after serial injections of BTX-A.
RESULTS: The beneficial effects of BTX-A occurred 1 week after the injection, whereas the adverse side-effects appeared within 1 week and lasted <2 weeks. BTX-A significantly improved muscle tone and gait 3 and 6 months after its serial injections compared to baseline (P <0.05).
CONCLUSIONS: Serial injections of BTX-A are effective and safe for children with spastic cerebral palsy. The sideeffects of serial injections of BTX-A are mild and selflimited.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24235067     DOI: 10.1007/s12519-013-0442-0

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  34 in total

1.  Botulinum toxin a injections to the upper limbs in children with cerebral palsy: duration of effect.

Authors:  Aviva Fattal-Valevski; Liora Sagi; Dafna Domenievitz
Journal:  J Child Neurol       Date:  2010-10-06       Impact factor: 1.987

2.  Changes in the electron microscopic structure of slow and fast skeletal muscle fibres of the mouse after the local injection of botulinum toxin.

Authors:  L W Duchen
Journal:  J Neurol Sci       Date:  1971-09       Impact factor: 3.181

Review 3.  Botulinum toxin. From poison to medicine.

Authors:  L E Davis
Journal:  West J Med       Date:  1993-01

4.  Botulinum toxin: mechanism of presynaptic blockade.

Authors:  I Kao; D B Drachman; D L Price
Journal:  Science       Date:  1976-09-24       Impact factor: 47.728

5.  Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity.

Authors:  Edward M Goldstein
Journal:  J Child Neurol       Date:  2006-03       Impact factor: 1.987

6.  Application of botulinum toxin in treatment of spasticity and functional improvements for children suffering from cerebral palsy.

Authors:  Ajsa Meholjic; Dijana Madjar
Journal:  Med Arh       Date:  2010

Review 7.  Botulinum toxin in children with cerebral palsy.

Authors:  Pratibha Singhi; Munni Ray
Journal:  Indian J Pediatr       Date:  2004-12       Impact factor: 1.967

8.  Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A.

Authors:  J A Chaddock; J R Purkiss; L M Friis; J D Broadbridge; M J Duggan; S J Fooks; C C Shone; C P Quinn; K A Foster
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

9.  High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy.

Authors:  Allison W Willis; Beth Crowner; Janice E Brunstrom; Abigail Kissel; Brad A Racette
Journal:  Dev Med Child Neurol       Date:  2007-11       Impact factor: 5.449

10.  Botulinum toxin B treatment in children with spastic movement disorders: a pilot study.

Authors:  Anette Schwerin; Steffen Berweck; Urban M Fietzek; Florian Heinen
Journal:  Pediatr Neurol       Date:  2004-08       Impact factor: 3.372

View more
  1 in total

Review 1.  Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.

Authors:  A Ferrari; M Manca; V Tugnoli; L Alberto
Journal:  Funct Neurol       Date:  2018 Jan/Mar
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.